Characterization of Glycosylation in Antibody Drugs

Characterization of Glycosylation in Antibody Drugs

CD BioGlyco has been working on glycosylation characterization for many years. We have developed systematic Solutions to provide customers with glycan analysis, glycopeptide analysis, and glycoprotein analysis services. Welcome customers from all over the world to cooperate with us!


Glycans are complex polymers composed of many monosaccharide molecules with covalent bonds, and glycans attached to antibodies exert a huge impact on the pharmacokinetics, efficacy, and safety of therapeutic antibodies. The glycans are classified into N-linked glycans, O-linked glycans, and glycosaminoglycans. Due to the complexity of glycan structures, antibody drugs are mixtures of proteins with different glycoforms.In 1986, the first therapeutic monoclonal antibody Orthoclone OKT3 was approved as an anti-rejection agent for kidney transplants. Currently, antibodies have been widely used in the treatment of various diseases, such as cancer and autoimmune diseases.

Characterization of Glycosylation in Antibody Drugs

Impact of Glycosylation on Antibody

Glycosylation affects antibody half-life, fragment crystallizable (Fc) effector function, and safety. Studies have shown that the half-life of antibodies with terminal sialic acids is significantly longer than that of non-sialylated antibodies. The reason is that the terminal sialic acid masks the galactose, protecting the antibody from rapid clearance. The Fc region of many antibodies carries core fucose, and deletion of core fucose enhances the affinity between Fc and FcγRIIIa, thereby increasing antibody-dependent cellular cytotoxicity (ADCC), such as non-fucose glycosylated humanized anti-M1 antibody. Furthermore, oligosaccharide chains attached to the surface of antibodies trigger specific immune responses to modulate the immunogenicity of antibodies.

Our Characterization Services

Given the impact of glycosylation on the half-life, ADCC, and immunogenicity of antibodies, CD BioGlyco provides customers with glycosylation characterization services in antibody drugs. Our services include but are not limited to:

  • Glycan analysis

We can characterize the released glycans by high-performance liquid chromatography (HPLC), capillary electrophoresis with laser-induced fluorescence detection (CE-LIF), and hydrophilic interaction liquid chromatography (HILIC).

  • Glycopeptide analysis

Mass spectrometry (MS) is the most advanced method for glycosylation analysis. The combination of capillary zone electrophoresis-electrospray ionization-MS (CZE-ESI-MS) and reversed-phase HPLC (RP-HPLC) enables the analysis of N-glycopeptides.

  • Glycoprotein analysis

ESI-MS is an efficient method to analyze the structure and the position of monosaccharide linkages. Analysis of intact glycoproteins is achieved by combining MS with other analytical methods.

CD BioGlyco provides our customers with high-quality, cost-effective, and hassle-free glycosylation characterization services. If you are interested in our services, please feel free to contact us. We are looking forward to being your indispensable assistant in your related reseach.


  1. Wang, Z.; et al. Antibody glycosylation: impact on antibody drug characteristics and quality control. Applied Microbiology and Biotechnology. 2020, 104(5): 1905-1914.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.